JP5261114B2 - Acid type liquid enteral nutrient - Google Patents
Acid type liquid enteral nutrient Download PDFInfo
- Publication number
- JP5261114B2 JP5261114B2 JP2008252242A JP2008252242A JP5261114B2 JP 5261114 B2 JP5261114 B2 JP 5261114B2 JP 2008252242 A JP2008252242 A JP 2008252242A JP 2008252242 A JP2008252242 A JP 2008252242A JP 5261114 B2 JP5261114 B2 JP 5261114B2
- Authority
- JP
- Japan
- Prior art keywords
- enteral nutrient
- liquid enteral
- protein
- acidic
- type liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000015097 nutrients Nutrition 0.000 title claims description 79
- 239000007788 liquid Substances 0.000 title claims description 56
- 239000002253 acid Substances 0.000 title description 4
- 230000002378 acidificating effect Effects 0.000 claims description 53
- 239000005018 casein Substances 0.000 claims description 30
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 30
- 235000021240 caseins Nutrition 0.000 claims description 30
- 235000018102 proteins Nutrition 0.000 claims description 26
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 25
- 239000003995 emulsifying agent Substances 0.000 claims description 23
- 230000001954 sterilising effect Effects 0.000 claims description 23
- 238000004659 sterilization and disinfection Methods 0.000 claims description 22
- 229940088594 vitamin Drugs 0.000 claims description 18
- 229930003231 vitamin Natural products 0.000 claims description 18
- 235000013343 vitamin Nutrition 0.000 claims description 15
- 239000011782 vitamin Substances 0.000 claims description 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 14
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 14
- 235000010755 mineral Nutrition 0.000 claims description 14
- 239000011707 mineral Substances 0.000 claims description 14
- 150000002632 lipids Chemical class 0.000 claims description 13
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 11
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 claims description 9
- 150000001720 carbohydrates Chemical class 0.000 claims description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
- 235000014633 carbohydrates Nutrition 0.000 claims description 7
- 150000007524 organic acids Chemical class 0.000 claims description 7
- 239000001384 succinic acid Substances 0.000 claims description 5
- 239000004310 lactic acid Substances 0.000 claims description 4
- 235000014655 lactic acid Nutrition 0.000 claims description 4
- 108010076119 Caseins Proteins 0.000 description 29
- 102000011632 Caseins Human genes 0.000 description 29
- 238000000034 method Methods 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 22
- 239000000203 mixture Substances 0.000 description 20
- 235000016709 nutrition Nutrition 0.000 description 18
- -1 fatty acid ester Chemical class 0.000 description 15
- 239000003921 oil Substances 0.000 description 14
- 235000019198 oils Nutrition 0.000 description 14
- 239000000243 solution Substances 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 238000005191 phase separation Methods 0.000 description 8
- 102000014171 Milk Proteins Human genes 0.000 description 7
- 108010011756 Milk Proteins Proteins 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 238000007922 dissolution test Methods 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 235000021239 milk protein Nutrition 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- 102000007544 Whey Proteins Human genes 0.000 description 6
- 238000004945 emulsification Methods 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 238000010438 heat treatment Methods 0.000 description 6
- 230000035764 nutrition Effects 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 235000004252 protein component Nutrition 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 230000009469 supplementation Effects 0.000 description 5
- 150000003722 vitamin derivatives Chemical class 0.000 description 5
- 235000021119 whey protein Nutrition 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 101800000263 Acidic protein Proteins 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000001465 calcium Nutrition 0.000 description 3
- 239000004227 calcium gluconate Substances 0.000 description 3
- 235000013927 calcium gluconate Nutrition 0.000 description 3
- 229960004494 calcium gluconate Drugs 0.000 description 3
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 3
- 229910052804 chromium Inorganic materials 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 235000011147 magnesium chloride Nutrition 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229910052750 molybdenum Inorganic materials 0.000 description 3
- 239000011733 molybdenum Substances 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 150000004804 polysaccharides Chemical class 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000003531 protein hydrolysate Substances 0.000 description 3
- 229940124272 protein stabilizer Drugs 0.000 description 3
- 239000011669 selenium Substances 0.000 description 3
- 229910052711 selenium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000012424 soybean oil Nutrition 0.000 description 3
- 239000003549 soybean oil Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229920003002 synthetic resin Polymers 0.000 description 3
- 239000000057 synthetic resin Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 239000011573 trace mineral Substances 0.000 description 3
- 235000013619 trace mineral Nutrition 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000206572 Rhodophyta Species 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 229930003448 Vitamin K Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000005486 organic electrolyte Substances 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000001508 potassium citrate Substances 0.000 description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000015870 tripotassium citrate Nutrition 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 235000019168 vitamin K Nutrition 0.000 description 2
- 239000011712 vitamin K Substances 0.000 description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 229940046010 vitamin k Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- KMZHZAAOEWVPSE-UHFFFAOYSA-N 2,3-dihydroxypropyl acetate Chemical compound CC(=O)OCC(O)CO KMZHZAAOEWVPSE-UHFFFAOYSA-N 0.000 description 1
- YNVZDODIHZTHOZ-UHFFFAOYSA-K 2-hydroxypropanoate;iron(3+) Chemical compound [Fe+3].CC(O)C([O-])=O.CC(O)C([O-])=O.CC(O)C([O-])=O YNVZDODIHZTHOZ-UHFFFAOYSA-K 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101150019464 ARAF gene Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229920000089 Cyclic olefin copolymer Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 239000004384 Neotame Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 235000019484 Rapeseed oil Nutrition 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 238000010793 Steam injection (oil industry) Methods 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000012615 aggregate Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 238000009455 aseptic packaging Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- GGDUFVMSYGVEMJ-UHFFFAOYSA-N butanedioic acid;octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)CCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O GGDUFVMSYGVEMJ-UHFFFAOYSA-N 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 229960004256 calcium citrate Drugs 0.000 description 1
- 229940062672 calcium dihydrogen phosphate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- OEUVSBXAMBLPES-UHFFFAOYSA-L calcium stearoyl-2-lactylate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O.CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O OEUVSBXAMBLPES-UHFFFAOYSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940108925 copper gluconate Drugs 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 229960000355 copper sulfate Drugs 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000011706 ferric diphosphate Substances 0.000 description 1
- 235000007144 ferric diphosphate Nutrition 0.000 description 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 1
- 229940036404 ferric pyrophosphate Drugs 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- CVRPVRHBAOPDIG-UHFFFAOYSA-N methyl 2-methylprop-2-enoate;2-(2-methylprop-2-enoyloxy)ethyl 1,3-dioxo-2-benzofuran-5-carboxylate Chemical compound COC(=O)C(C)=C.CC(=C)C(=O)OCCOC(=O)C1=CC=C2C(=O)OC(=O)C2=C1 CVRPVRHBAOPDIG-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000019412 neotame Nutrition 0.000 description 1
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 description 1
- 108010070257 neotame Proteins 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 235000016236 parenteral nutrition Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229910001392 phosphorus oxide Inorganic materials 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical class [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000011112 polyethylene naphthalate Substances 0.000 description 1
- 229920013716 polyethylene resin Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920005672 polyolefin resin Polymers 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229940048914 protamine Drugs 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 235000021568 protein beverage Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- JHYAVWJELFKHLM-UHFFFAOYSA-H tetrasodium;2-hydroxypropane-1,2,3-tricarboxylate;iron(2+) Chemical compound [Na+].[Na+].[Na+].[Na+].[Fe+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O JHYAVWJELFKHLM-UHFFFAOYSA-H 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明は経管投与または経口摂取で栄養補給を必要とする高齢者や患者などに対して、効率的にたんぱく質、脂質、糖質、ビタミン、ミネラルなどの補給ができる液状経腸栄養剤に関する。
更に詳しくは、栄養価の高い良質のたんぱく質として乳たんぱく質であるカゼイン加水分解物を使用し、油脂を特定の乳化剤で乳化し、pH3〜4の酸性域において加熱殺菌後も乳化安定性が良好で、粘度が低く、チューブ流動性に優れ、チューブに詰まらない酸性タイプ液状経腸栄養剤に関するものである。
The present invention relates to a liquid enteral nutrient capable of efficiently supplementing proteins, lipids, carbohydrates, vitamins, minerals and the like to elderly people and patients who need nutritional supplementation by tube administration or oral intake.
More specifically, casein hydrolyzate, which is a milk protein, is used as a high-quality protein with high nutritional value, fat and oil are emulsified with a specific emulsifier, and the emulsion stability is good even after heat sterilization in an acidic region of pH 3-4. The present invention relates to an acidic liquid enteral nutrient that has low viscosity, excellent tube fluidity, and does not clog the tube.
経腸栄養法は経静脈栄養法に比べて生理的で、小腸粘膜の機能を維持し、バクテリアルトランスロケーションを予防することが可能な方法で、合併症の予防、在院日数の短縮が可能になるなど有用性が高い。経腸栄養法に用いられる液状の経腸栄養剤は、体に必要な各種の栄養素であるたんぱく質、脂質、糖質、ビタミン、ミネラルなどが十分量、バランスよく配合されており、通常の食事などを摂取できない手術前後の患者、高齢者などに栄養補給を行い、その体力などの回復や治癒を促進させるものとして欠かせないものである。
経腸栄養法で使用される経腸栄養剤は、たんぱく質成分として、乳たんぱく質や大豆たんぱく質などが使用されているが、たんぱく質成分の多くは、酸性側に等電点を有するため、酸性域では、たんぱく質と分散媒との静電的相互作用が損なわれ、たんぱく質は凝集、沈殿、相分離などが生じやすい。また、このような栄養組成物は、苛酷な均質化処理や加熱殺菌処理を施すため、たんぱく質−脂質複合体の構造変化が引き起こされ、乳化安定性が損なわれてしまい、消費者に供するに十分な栄養組成物が調製されるには至っていない。このため、現在市場に出回っている経腸栄養剤の多くはpH6.0〜7.5程度の中性タイプのものである。
従来から使用されている中性タイプの経腸栄養剤は、チューブを介して胃中に投与すると、たんぱく質成分が胃液と接触した際、凝集する傾向にあり、そのため、チューブ先端にたんぱく質の凝集ができ、チューブ詰まりが生じることがあった。このため、経腸栄養剤のpHをあらかじめ酸性域で調製し、たんぱく質を安定して分散させることができれば、たんぱく質成分が胃液と接触しても、たんぱく質成分が凝集し難くなり、チューブ詰まりを抑制することが可能となる。
Enteral nutrition is more physiological than parenteral nutrition, maintains the function of the mucous membrane of the small intestine, and prevents bacterial translocation, which can prevent complications and shorten hospital stays. It is highly useful. Liquid enteral nutrients used for enteral nutrition include various nutrients necessary for the body, such as proteins, lipids, carbohydrates, vitamins, minerals, etc. It is indispensable as a nutritional supplement for patients before and after surgery, who cannot take in, and the elderly, and to promote recovery and healing of their physical strength.
Enteral nutrients used in enteral nutrition methods use milk protein, soybean protein, etc. as protein components, but most protein components have an isoelectric point on the acidic side, so in the acidic range The electrostatic interaction between the protein and the dispersion medium is impaired, and the protein is likely to aggregate, precipitate, and phase separate. In addition, since such a nutritional composition is subjected to severe homogenization treatment and heat sterilization treatment, the structural change of the protein-lipid complex is caused, and the emulsion stability is impaired, which is sufficient for use by consumers. No nutritional composition has been prepared. For this reason, many enteral nutrients currently on the market are of the neutral type with a pH of about 6.0 to 7.5.
Conventionally used neutral type enteral nutrients tend to aggregate when the protein component comes into contact with the gastric juice when administered to the stomach via a tube, so that protein aggregation occurs at the tube tip. And tube clogging may occur. For this reason, if the pH of the enteral nutrient is adjusted in advance in the acidic range and the protein can be stably dispersed, the protein component will not easily aggregate even if the protein component comes into contact with the gastric juice, and tube clogging will be suppressed. It becomes possible to do.
このように、これまでの経腸栄養剤は、上述のような課題点を有しており、市場では、たんぱく質、脂質、糖質、ビタミン、ミネラルなどが十分量、バランスよく配合され、さらに、乳化安定性が良好で、粘度が低く、チューブ流動性に優れ、チューブに詰まらない液状経腸栄養剤が望まれていた。
上記のような課題に対して、例えば、たんぱく質を含有する酸性タイプの飲料組成物については、既に文献に記載されており、すなわち、HLB9以上のポリグリセリン脂肪酸エステル、及び0.1〜5.0w/w%のたんぱく質を含有する、pH3.0〜4.2の酸性飲料(特許文献1参照)やホエーたんぱく質濃縮物、糖アルコール及び高甘味度甘味料を含有し、ホエーたんぱく質の含有量が0.8〜5w/v%、pHが3.2〜3.8の低カロリー酸性たんぱく飲料(特許文献2参照)がある。しかし、たんぱく質濃度を3.5w/v%以上に調製した場合、たんぱく質の分散安定性が著しく低下し、加熱殺菌時の加熱などによって、たんぱく質が凝集・沈殿したり、ゲル化したりする傾向にあり、貯蔵安定性や流動性が劣るものであった。また、たんぱく質濃度が高く、貯蔵安定性や流動性に優れた酸性タイプの飲料組成物などの酸性液状経腸栄養剤は、これまで知られていなかった。
Thus, conventional enteral nutrients have the above-mentioned problems, and in the market, proteins, lipids, carbohydrates, vitamins, minerals, etc. are blended in sufficient amounts and in a well-balanced manner. A liquid enteral nutrient that has good emulsification stability, low viscosity, excellent tube fluidity, and does not clog the tube has been desired.
For the above problems, for example, an acidic type beverage composition containing a protein has already been described in the literature, that is, a polyglycerin fatty acid ester of HLB9 or higher, and 0.1 to 5.0 w. Contains w / w% protein, pH 3.0-4.2 acidic beverage (see Patent Document 1), whey protein concentrate, sugar alcohol and high-intensity sweetener, and contains 0 whey protein. There is a low calorie acidic protein beverage having a pH of 3.2 to 3.8 (see Patent Document 2). However, when the protein concentration is adjusted to 3.5 w / v% or more, the dispersion stability of the protein is remarkably lowered, and the protein tends to aggregate / precipitate or gel due to heating during heat sterilization. The storage stability and fluidity were inferior. Further, an acidic liquid enteral nutrient such as an acidic type beverage composition having a high protein concentration and excellent storage stability and fluidity has not been known so far.
また、ゲル化剤を使用した方法として、例えば、発酵乳などの蛋白食品に果汁、有機酸などが添加された酸性下において、蛋白質粒子の凝集、沈殿、相分離などが生じるのを防止することができる酸性蛋白安定化剤として、紅藻から抽出される硫酸多糖類を含有することを特徴とする酸性蛋白安定化剤(特許文献3参照)がある。しかし、この酸性たんぱく食品は、紅藻から抽出される硫酸多糖類をたんぱく質安定化剤として用いるので、汎用性に乏しく、また、粘度が高くなるという課題があった。
さらに、タンパク質の安定性に優れ、低pHにおいても調製可能な酸乳ゲル組成物として、ジェランガム、寒天または大豆多糖類を含有することを特徴とする酸乳ゲル組成物(特許文献4参照)がある。しかし、この技術は、たんぱく質安定化剤として汎用されている大豆食物繊維やペクチンを用いて乳たんぱく成分を安定化する技術であるが、たんぱく質やたんぱく加水分解物の含有量が多い酸性飲食品には必ずしも適さない場合り、また、粘度が高くなる課題を有していた。
In addition, as a method using a gelling agent, for example, aggregation of protein particles, precipitation, phase separation and the like are prevented from occurring under acidic conditions in which fruit juice, organic acid, or the like is added to protein foods such as fermented milk. There is an acidic protein stabilizer (see Patent Document 3) characterized in that it contains a sulfated polysaccharide extracted from red algae. However, since this acidic protein food uses sulfated polysaccharide extracted from red algae as a protein stabilizer, it has a problem of low versatility and high viscosity.
Furthermore, an acid milk gel composition characterized by containing gellan gum, agar, or soybean polysaccharide as an acid milk gel composition that is excellent in protein stability and can be prepared even at low pH (see Patent Document 4). is there. However, this technology stabilizes milk protein components using soy dietary fiber and pectin, which are widely used as protein stabilizers, but it can be applied to acidic foods and drinks with high protein and protein hydrolyzate contents. Is not always suitable, and has a problem of increasing the viscosity.
従って、栄養価の高い良質のたんぱく質として乳たんぱく質を使用し、栄養素が十分量、バランスよく配合され、加熱殺菌処理しても乳化安定性が良好で、粘度が低く、チューブ流動性に優れ、チューブに詰まらない酸性タイプ液状経腸栄養剤が待望されていた。 Therefore, milk protein is used as a high-quality protein with high nutritional value, a sufficient amount of nutrients are blended in a well-balanced state, emulsion stability is good even after heat sterilization, low viscosity, excellent tube fluidity, tube There is a long-awaited acidic liquid enteral nutrient that does not clog.
本発明の目的は、上述の状況を鑑みてなされたもので、液状経腸栄養剤を酸性にしてもカゼイン加水分解物と特定の乳化剤を使用して調製することにより、製造工程中の均質化処理や加熱殺菌処理後も乳化安定性が良好に確保され、粘度が低く、チューブ流動性に優れ、栄養補給を必要とする高齢者や患者などへの栄養補給の際に摂取できるようにした酸性タイプ液状経腸栄養剤を提供するものである。 The object of the present invention has been made in view of the above-mentioned situation, and even when the liquid enteral nutrient is acidified, it is prepared using a casein hydrolyzate and a specific emulsifier, thereby homogenizing during the manufacturing process. Acidity that ensures good emulsification stability after treatment and heat sterilization, low viscosity, excellent tube fluidity, and can be ingested during nutritional supplementation for the elderly and patients who need nutritional supplementation A type liquid enteral nutrient is provided.
本発明者らは、前記目的を達成すべく鋭意研究を重ねた結果、特定の分子量のカゼイン加水分解物と特定の乳化剤を使用して調製することにより、たんぱく質、脂質、糖質、ビタミン、ミネラルなどが十分量、バランスよく配合され、加熱殺菌後も乳化安定性が良好で、粘度が低く、チューブ流動性に優れ、チューブに詰まらない酸性タイプ液状経腸栄養剤を得られることを見出し、この知見に基づき本発明を完成するに至った。
すなわち、本発明は、以下の(1)〜(4)に示したものである。
(1)たんぱく質、脂質、糖質、ビタミン、ミネラルを含有し、pHが3〜4の範囲の酸性タイプ液状経腸栄養剤において、たんぱく質が平均分子量500〜10000ダルトンのカゼイン加水分解物を使用し、乳化剤が有機酸モノグリセライドを0.2〜1重量%配合し、加熱殺菌後の経腸栄養剤の粘度が3〜30mPa・sである酸性タイプ液状経腸栄養剤。
(2)有機酸モノグリセライドがコハク酸モノグリセライドまたはジアセチル酒石酸モノグリセライドから選ばれる少なくとも1種の乳化剤である上記(1)に記載の酸性タイプ液状経腸栄養剤。
(3)カゼイン加水分解物の含有量が2〜8重量%である上記(1)または(2)に記載の酸性タイプ液状経腸栄養剤。
As a result of intensive studies to achieve the above-mentioned object, the present inventors have prepared proteins, lipids, carbohydrates, vitamins, minerals by preparing using a casein hydrolyzate having a specific molecular weight and a specific emulsifier. It is found that an acidic type liquid enteral nutrient can be obtained in a sufficient amount and well-balanced, with good emulsification stability after heat sterilization, low viscosity, excellent tube fluidity, and not clogging the tube. The present invention has been completed based on the findings.
That is, this invention is shown to the following (1)-(4).
(1) An acidic liquid enteral nutrient containing protein, lipid, sugar, vitamins and minerals and having a pH in the range of 3 to 4, using a casein hydrolyzate having an average molecular weight of 500 to 10,000 daltons. An acidic liquid enteral nutrient wherein the emulsifier contains 0.2 to 1% by weight of organic acid monoglyceride and the viscosity of the enteral nutrient after heat sterilization is 3 to 30 mPa · s.
(2) The acidic liquid enteral nutrient according to (1) above, wherein the organic acid monoglyceride is at least one emulsifier selected from succinic acid monoglyceride or diacetyltartaric acid monoglyceride.
(3) The acidic type liquid enteral nutrient according to (1) or (2) above, wherein the content of casein hydrolyzate is 2 to 8% by weight.
以上述べたように、本発明の酸性タイプ液状経腸栄養剤は、特定の分子量のカゼイン加水分解物と特定の乳化剤を使用して調製することにより、たんぱく質、脂質、糖質、ビタミン、ミネラルなどが十分量、バランスよく配合され、製造工程中の均質化処理や加熱殺菌処理後も乳化安定性が良好で、粘度が低く、チューブ流動性に優れ、チューブに詰まらず、栄養補給を必要とする高齢者や患者などへの栄養補給の際に摂取できるようにした酸性タイプ液状経腸栄養剤を提供することができる。 As described above, the acidic type liquid enteral nutrient of the present invention is prepared by using a casein hydrolyzate having a specific molecular weight and a specific emulsifier, so that proteins, lipids, carbohydrates, vitamins, minerals, etc. Is mixed in a sufficient amount and well-balanced, has good emulsification stability after homogenization and heat sterilization in the manufacturing process, has low viscosity, excellent tube fluidity, does not clog the tube, and requires nutritional supplementation It is possible to provide an acidic type liquid enteral nutrient that can be ingested during nutritional supplementation for the elderly and patients.
以下、本発明の酸性タイプ液状経腸栄養剤を詳細に説明する。
本発明の酸性タイプ液状経腸栄養剤で使用するたんぱく質原料としては、平均分子量が500〜10000ダルトン、好ましくは1000〜7500ダルトンのカゼイン加水分解物であれば、特に限定されるものではない。また、前記平均分子量の範囲内であれば、異なる平均分子量のカゼイン加水分解物を組み合わせて使用しても良い。なお、本発明において平均分子量とは、重量平均分子量を意味する。
カゼイン加水分解物の平均分子量が500ダルトンより小さいと、脂質を乳化し、加熱殺菌した際の乳化安定性を保持できなくなるため、好ましくない。また、カゼイン加水分解物の平均分子量が10000ダルトンより大きいと、経腸栄養剤のpHを4以下にすると、不溶性の凝集物や沈殿物を生じ、液状でなくなるので、経管投与の際にチューブ閉塞の原因となり、投与が困難となるため、好ましくない。
本発明に使用することのできる具体的なカゼイン加水分解物としては、HCP102(タツア・ジャパン株式会社)、エマルアップやC800(森永乳業株式会社)が挙げられる。
Hereinafter, the acidic type liquid enteral nutrient of the present invention will be described in detail.
The protein raw material used in the acidic type liquid enteral nutrient of the present invention is not particularly limited as long as it is a casein hydrolyzate having an average molecular weight of 500 to 10,000 daltons, preferably 1000 to 7500 daltons. Moreover, you may use it combining the casein hydrolyzate of different average molecular weight, if it is in the range of the said average molecular weight. In the present invention, the average molecular weight means a weight average molecular weight.
If the average molecular weight of the casein hydrolyzate is less than 500 daltons, it is not preferable because the emulsion stability cannot be maintained when the lipid is emulsified and heat-sterilized. In addition, if the average molecular weight of the casein hydrolyzate is greater than 10,000 daltons, insoluble nutrients and precipitates are formed when the pH of the enteral nutrient is adjusted to 4 or less. This is not preferable because it causes obstruction and administration becomes difficult.
Specific casein hydrolysates that can be used in the present invention include HCP102 (Tatsua Japan Co., Ltd.), Emalup and C800 (Morinaga Dairy Co., Ltd.).
本発明において、カゼイン加水分解物の平均分子量を求める方法は、当該技術分野における慣用技術ならびに知識がそのまま、もしくは適宜変更を加えた形で適用され、代表的にはゲルろ過クロマトグラフィーが挙げられる。すなわち、高速液体クロマトグラフィー装置に紫外可視分光検出器を連結し、カゼイン加水分解物をゲルろ過カラムに供し、溶離液を流すことによって溶離したカゼイン加水分解物を分析する方法である。この方法を用いた場合、カゼイン加水分解物の平均分子量は、紫外可視分光検出器の感度から高速液体クロマトグラフィーのデータ処理装置に従って計算することにより、求めることができる。
本発明の酸性タイプ液状経腸栄養剤のカゼイン加水分解物の含有量は、2〜8重量%、好ましくは3〜6重量%の範囲内である。カゼイン加水分解物の含有量が2重量%より少ないと、窒素源として栄養学的に不十分となるため、好ましくない。また、カゼイン加水分解物の含有量が8重量%より多いと、窒素源として過剰摂取となるため、好ましくない。
In the present invention, the method for determining the average molecular weight of the casein hydrolyzate is applied with conventional techniques and knowledge in the technical field as they are or with appropriate modifications, and typically includes gel filtration chromatography. That is, this is a method of analyzing the eluted casein hydrolyzate by connecting a UV-visible spectroscopic detector to a high performance liquid chromatography apparatus, applying the casein hydrolyzate to a gel filtration column, and flowing an eluent. When this method is used, the average molecular weight of the casein hydrolyzate can be obtained by calculating from the sensitivity of the UV-visible spectroscopic detector according to a data processor of high performance liquid chromatography.
The content of the casein hydrolyzate of the acidic liquid enteral nutrient of the present invention is in the range of 2 to 8% by weight, preferably 3 to 6% by weight. If the casein hydrolyzate content is less than 2% by weight, it is not preferable because it becomes nutritionally insufficient as a nitrogen source. Further, if the content of the casein hydrolyzate is more than 8% by weight, it is not preferable because it is excessive intake as a nitrogen source.
本発明の酸性タイプ液状経腸栄養剤には、本発明の主旨を逸脱しない範囲内で、従来から食品に慣用されるたんぱく質加水分解物を配合してもよい。たんぱく質加水分解物の由来としては、カゼイン以外に、乳清、トータル・ミルク・プロテイン(TMP)、ミルク・プロテイン・コンセントレート(MPC)などの乳蛋白、卵白、コラーゲン、プロタミンなどの動物性蛋白、大豆、小麦、とうもろこしなどの植物性蛋白などから製造されるものが挙げられる。 The acid type liquid enteral nutrient of the present invention may be blended with a protein hydrolyzate conventionally used in foods without departing from the gist of the present invention. In addition to casein, protein hydrolyzate is derived from milk proteins such as whey, total milk protein (TMP), milk protein concentrate (MPC), animal proteins such as egg white, collagen, protamine, Examples include those produced from vegetable proteins such as soybeans, wheat, and corn.
本発明の酸性タイプ液状経腸栄養剤に用いる乳化剤は、有機酸モノグリセライドであり、コハク酸モノグリセライド、ジアセチル酒石酸モノグリセライド、クエン酸モノグリセライド、酢酸モノグリセライド、乳酸モノグリセライドなどが挙げられる。その中でも、コハク酸モノグリセライド、ジアセチル酒石酸モノグリセライドが好ましい。
本発明に使用することのできる具体的な乳化剤としては、ポエムB−10やポエムW−10(理研ビタミン株式会社)、サンソフトNo.681NUやサンソフトNo.641D(太陽化学株式会社)が挙げられる。
本発明の酸性タイプ液状経腸栄養剤に配合される乳化剤の配合量は、0.2〜1重量%、好ましくは0.3〜0.5重量%の範囲である。
乳化剤の配合量が、0.2重量%より少ないと、乳化剤の効果が十分発揮できず、保存中に乳化状態を保持できなくなるため、好ましくない。また、1重量%を越えると、乳化剤の風味が強くなるため、食品として好ましくない。
The emulsifier used in the acidic type liquid enteral nutrient of the present invention is an organic acid monoglyceride, and examples thereof include succinic acid monoglyceride, diacetyltartaric acid monoglyceride, citric acid monoglyceride, acetic acid monoglyceride, and lactic acid monoglyceride. Among these, succinic acid monoglyceride and diacetyltartaric acid monoglyceride are preferable.
Specific emulsifiers that can be used in the present invention include Poem B-10, Poem W-10 (Riken Vitamin Co., Ltd.), Sunsoft No. 681NU and Sunsoft No. 641D (Taiyo Chemical Co., Ltd.).
The compounding quantity of the emulsifier mix | blended with the acidic type liquid enteral nutrient of this invention is 0.2 to 1 weight%, Preferably it is the range of 0.3 to 0.5 weight%.
If the blending amount of the emulsifier is less than 0.2% by weight, the effect of the emulsifier cannot be sufficiently exhibited, and the emulsified state cannot be maintained during storage, which is not preferable. On the other hand, if it exceeds 1% by weight, the flavor of the emulsifier becomes strong, which is not preferable for food.
なお、本発明の目的を逸脱しない範囲において、有機酸モノグリセライド以外の汎用される乳化剤、例えば、グリセリン脂肪酸エステル、ポリグリセリン脂肪酸エステル、ショ糖脂肪酸エステル、ソルビタン脂肪酸エステル、プロピレングリコール脂肪酸エステルなどを追加して使用することができる。 In addition, within the scope not departing from the object of the present invention, a general-purpose emulsifier other than organic acid monoglyceride, for example, glycerin fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester and the like are added. Can be used.
本発明の酸性タイプ液状経腸栄養剤に用いる脂質としては、従来使用されているものはいずれも可能であり、例えば、アマニ油、エゴマ油、オリーブ油、ごま油、米ぬか油、サフラワー油、シソ油、大豆油、とうもろこし油、ナタネ油、胚芽油、パーム油、パーム核油、ひまわり油、綿実油、やし油、落花生油等の植物性油脂、魚油、乳脂等の動物性油脂、中鎖脂肪酸、高度不飽和脂肪酸などが挙げられる。これらは1種用いてもよいし、2種以上を組み合わせてもよい。また、その他にDHA、EPA、ジアシルグリセロールなどの加工製剤も添加することができる。
本発明の酸性タイプ液状経腸栄養剤に配合される脂質の配合量は、1〜3重量%好ましくは1.5〜2.5重量%の範囲である。
As the lipid used for the acidic liquid enteral nutrient of the present invention, any conventionally used lipid can be used. For example, linseed oil, egoma oil, olive oil, sesame oil, rice bran oil, safflower oil, perilla oil Vegetable oils such as soybean oil, corn oil, rapeseed oil, germ oil, palm oil, palm kernel oil, sunflower oil, cottonseed oil, palm oil, peanut oil, animal oils such as fish oil, milk fat, medium chain fatty acids, Examples include highly unsaturated fatty acids. These may be used alone or in combination of two or more. In addition, processed preparations such as DHA, EPA, and diacylglycerol can be added.
The compounding quantity of the lipid mix | blended with the acidic type liquid enteral nutrient of this invention is 1-3 weight%, Preferably it is the range of 1.5-2.5 weight%.
本発明の酸性タイプ液状経腸栄養剤で使用する糖類としては、従来から、食品に慣用されるものでよく、例えば、澱粉、デキストリンやブドウ糖および果糖などの単糖類、マルトースおよび乳糖などの二糖類、砂糖、グラニュー糖、水飴、還元水飴、はちみつ、異性化糖、転化糖、オリゴ糖(イソマルトオリゴ糖、還元キシロオリゴ糖、還元ゲンチオオリゴ糖、キシロオリゴ糖、ゲンチオオリゴ糖、ニゲロオリゴ糖、テアンデオリゴ糖、大豆オリゴ糖など)、粉飴、トレハロース、糖アルコール(マルチトール、エリスリトール、ソルビトール、パラチニット、キシリトール、ラクチトールなど)、砂糖結合水飴(カップリングシュガー)などが挙げられる。これらは1種用いてもよいし、2種以上を組み合わせてもよい。
また、従来公知もしくは将来知られうる甘味成分も糖類の代わりに用いることができる。具体的には、アスパルテーム、アセスルファムカリウム、スクラロース、アリテーム、ネオテーム、カンゾウ抽出物(グリチルリチン)、サッカリン、サッカリンナトリウム、ステビア抽出物、ステビア末などの甘味成分を用いても良い。
The saccharides used in the acidic liquid enteral nutrient of the present invention may be those conventionally used in foods, for example, monosaccharides such as starch, dextrin, glucose and fructose, and disaccharides such as maltose and lactose. , Sugar, granulated sugar, starch syrup, reduced starch syrup, honey, isomerized sugar, invert sugar, oligosaccharide Etc.), flour koji, trehalose, sugar alcohol (such as maltitol, erythritol, sorbitol, palatinit, xylitol, lactitol), sugar-linked starch syrup (coupling sugar), and the like. These may be used alone or in combination of two or more.
In addition, conventionally known or future sweet ingredients can also be used in place of sugars. Specifically, sweet ingredients such as aspartame, acesulfame potassium, sucralose, aritem, neotame, licorice extract (glycyrrhizin), saccharin, saccharin sodium, stevia extract, stevia powder and the like may be used.
本発明の酸性タイプ液状経腸栄養剤を製造する際には、製品の種類に応じて通常用いられる適当なビタミンやミネラルなどの成分を配合することが出来る。
本発明の酸性タイプ液状経腸栄養剤に用いるビタミンとしては、ビタミンB1、ビタミンB2、ビタミンB6、ビタミンB12、ナイアシン、パントテン酸、葉酸、ビオチン、ビタミンC、ビタミンA、ビタミンD、ビタミンE、ビタミンKなどが挙げられ、これら複数をできる限り組み合わせて配合するのが好ましい。ビタミンとして、ビタミン誘導体を使用してもよい。
When producing the acidic type liquid enteral nutrient of the present invention, components such as appropriate vitamins and minerals which are usually used can be blended depending on the kind of the product.
As vitamins used in the acidic type liquid enteral nutrient of the present invention, vitamin B1, vitamin B2, vitamin B6, vitamin B12, niacin, pantothenic acid, folic acid, biotin, vitamin C, vitamin A, vitamin D, vitamin E, vitamin K etc. are mentioned, It is preferable to mix | blend these plurality in combination as much as possible. A vitamin derivative may be used as the vitamin.
ビタミンの配合量としては、酸性タイプ液状経腸栄養剤100mLあたり、下記の範囲が適当である。
ビタミンB1 0.1〜40mg、好ましくは0.3〜25mg
ビタミンB2 0.1〜20mg、好ましくは0.33〜12mg
ビタミンB6 0.1〜60mg、好ましくは0.3〜10mg
ビタミンB12 0.1〜100μg、好ましくは0.60〜60μg
ナイアシン 1〜300mg、好ましくは3.3〜60mg
パントテン酸 0.1〜55mg、好ましくは1.65〜30mg
葉酸 10〜1000μg、好ましくは60〜200μg
ビオチン 1〜1000μg、好ましくは14〜500μg
ビタミンC 10〜2000mg、好ましくは24〜1000mg
ビタミンA 0〜3000μg、好ましくは135〜600μg
ビタミンD 0.1〜50μg、好ましくは1.5〜5.0μg
ビタミンE 1〜800mg、好ましくは2.4〜150mg
ビタミンK 0.5〜1000μg、好ましくは2〜700μg
As a compounding quantity of a vitamin, the following range is suitable per 100 mL of acidic type liquid enteral nutrients.
Vitamin B1 0.1-40 mg, preferably 0.3-25 mg
Vitamin B2 0.1-20 mg, preferably 0.33-12 mg
Vitamin B6 0.1-60 mg, preferably 0.3-10 mg
Vitamin B12 0.1-100 μg, preferably 0.60-60 μg
Niacin 1-300 mg, preferably 3.3-60 mg
Pantothenic acid 0.1-55 mg, preferably 1.65-30 mg
Folic acid 10-1000 μg, preferably 60-200 μg
Biotin 1-1000 μg, preferably 14-500 μg
Vitamin C 10-2000 mg, preferably 24-1000 mg
Vitamin A 0-3000 μg, preferably 135-600 μg
Vitamin D 0.1-50 μg, preferably 1.5-5.0 μg
Vitamin E 1-800 mg, preferably 2.4-150 mg
Vitamin K 0.5-1000 μg, preferably 2-700 μg
本発明の酸性タイプ液状経腸栄養剤に用いるミネラルとして、ナトリウム、カリウム、カルシウム、マグネシウム、リン、鉄、銅、亜鉛、マンガン、セレン、ヨウ素、クロムおよびモリブデンなどが挙げられ、これら複数をできる限り組み合わせて配合するのが好ましい。これらは、無機電解質成分として配合されていても良いし、有機電解質成分、として配合されていてもよい。無機電解質成分としては、例えば、塩化物、硫酸化物、炭酸化物、リン酸化物などのアルカリ金属またはアルカリ土類金属の塩類が挙げられる。また、有機電解質成分としては、有機酸、例えばクエン酸、乳酸、アミノ酸(例えば、グルタミン酸、アスパラギン酸など)、アルギン酸、リンゴ酸またはグルコン酸と、無機塩基、例えばアルカリ金属またはアルカリ土類金属との塩類が挙げられる。例えば、塩化カルシウム、クエン酸カルシウム、グリセロリン酸カルシウム、グルコン酸カルシウム、水酸化カルシウム、ステアリン酸カルシウム、ステアロイル乳酸カルシウム、炭酸カルシウム、乳酸カルシウム、ピロリン酸二水素カルシウム、硫酸カルシウム、リン酸三カルシウム、リン酸一水素カルシウム、リン酸二水素カルシウム、未焼成カルシウム、塩化マグネシウム、ステアリン酸マグネシウム、炭酸マグネシウム、硫酸マグネシウム、リン酸三マグネシウム、塩化第二鉄、クエン酸第一鉄ナトリウム、クエン酸鉄、クエン酸鉄アンモニウム、グルコン酸第一鉄、乳酸鉄、ピロリン酸第二鉄、硫酸第一鉄、グルコン酸亜鉛、硫酸亜鉛、グルコン酸銅、硫酸銅などが挙げられる。また、ヨウ素、セレン、クロム、モリブデン、マンガンなどは、高濃度の微量元素化合物を含有する培地内で培養して得られる微量元素蓄積性を有する微生物由来の微量元素含有微生物菌体を用いても良い。 Examples of minerals used in the acidic type liquid enteral nutrient of the present invention include sodium, potassium, calcium, magnesium, phosphorus, iron, copper, zinc, manganese, selenium, iodine, chromium and molybdenum, and more than one of these is possible. It is preferable to combine them. These may be mix | blended as an inorganic electrolyte component, and may be mix | blended as an organic electrolyte component. Examples of the inorganic electrolyte component include alkali metal or alkaline earth metal salts such as chlorides, sulfates, carbonates, and phosphorus oxides. The organic electrolyte component includes an organic acid such as citric acid, lactic acid, amino acid (such as glutamic acid and aspartic acid), alginic acid, malic acid or gluconic acid and an inorganic base such as an alkali metal or alkaline earth metal. Examples include salts. For example, calcium chloride, calcium citrate, calcium glycerophosphate, calcium gluconate, calcium hydroxide, calcium stearate, calcium stearoyl lactate, calcium carbonate, calcium lactate, dihydrogen pyrophosphate, calcium sulfate, tricalcium phosphate, monophosphate Calcium hydrogen, calcium dihydrogen phosphate, uncalcined calcium, magnesium chloride, magnesium stearate, magnesium carbonate, magnesium sulfate, trimagnesium phosphate, ferric chloride, sodium ferrous citrate, iron citrate, iron citrate Examples include ammonium, ferrous gluconate, iron lactate, ferric pyrophosphate, ferrous sulfate, zinc gluconate, zinc sulfate, copper gluconate, and copper sulfate. In addition, iodine, selenium, chromium, molybdenum, manganese, etc. can be used even if trace element-containing microbial cells derived from microorganisms having trace element accumulation obtained by culturing in a medium containing a high concentration of trace element compounds. good.
ミネラルの配合量としては、酸性タイプ液状経腸栄養剤100mLあたり、下記の範囲が適当である。
ナトリウム 5〜6000mg、好ましくは10〜3500mg
カリウム 1〜3500mg、好ましくは25〜1800mg
マグネシウム 1〜740mg、好ましくは25〜300mg
カルシウム 10〜2300mg、好ましくは250〜600mg
リン 1〜3500mg、好ましくは25〜1500mg
鉄 0.1〜55mg、好ましくは1〜10mg
銅 0.01〜10mg、好ましくは0.1〜6mg
亜鉛 0.1〜30mg、好ましくは1〜15mg
マンガン 0.01〜11mg、好ましくは0.1〜4mg
セレン 0.1〜450μg、好ましくは1〜35μg
クロム 0.1〜40μg、好ましくは1〜35μg
ヨウ素 0.1〜3000μg、好ましくは1〜150μg
モリブデン 0.1〜320μg、好ましくは1〜25μg
As the blending amount of the mineral, the following range is appropriate per 100 mL of the acidic type liquid enteral nutrient.
Sodium 5-6000mg, preferably 10-3500mg
Potassium 1-3500 mg, preferably 25-1800 mg
Magnesium 1-740 mg, preferably 25-300 mg
Calcium 10-2300 mg, preferably 250-600 mg
Phosphorus 1-3500 mg, preferably 25-1500 mg
Iron 0.1-55 mg, preferably 1-10 mg
Copper 0.01-10 mg, preferably 0.1-6 mg
Zinc 0.1-30mg, preferably 1-15mg
Manganese 0.01-11 mg, preferably 0.1-4 mg
Selenium 0.1-450 μg, preferably 1-35 μg
Chromium 0.1-40 μg, preferably 1-35 μg
Iodine 0.1-3000 μg, preferably 1-150 μg
Molybdenum 0.1-320 μg, preferably 1-25 μg
本発明の酸性タイプ液状経腸栄養剤の1mLあたりの熱量としては、特に限定されるものではないが、0.5〜2.0kcal、好ましくは0.75〜1.5kcalである。酸性タイプ液状経腸栄養剤の1mLあたりの熱量が0.5kcalより低いと、栄養学的に十分な熱量が得られない。酸性タイプ液状経腸栄養剤の1mLあたりの熱量が、2.0kcalより高いと、酸性タイプ液状経腸栄養剤の加熱殺菌後の粘度が高くなる。 The amount of heat per mL of the acidic liquid enteral nutrient of the present invention is not particularly limited, but is 0.5 to 2.0 kcal, preferably 0.75 to 1.5 kcal. If the amount of heat per mL of the acidic liquid enteral nutrient is lower than 0.5 kcal, a nutritionally sufficient amount of heat cannot be obtained. If the amount of heat per mL of the acidic type liquid enteral nutrient is higher than 2.0 kcal, the viscosity of the acidic type liquid enteral nutrient after heat sterilization becomes high.
以上、本発明の酸性タイプ液状経腸栄養剤について説明したが、本発明は、これらに限定されるものではなく、必要に応じて、他の成分類や添加剤などを添加してもよい。例えば、クエン酸、酒石酸、リンゴ酸、コハク酸、乳酸、グリセリン、プロピレングリコール、アラビアゴム、色素、香料、保存剤など、通常の食品原料として使用されている添加剤などを適宜添加してもよい。
本発明において製造に際しては上記に説明した組成範囲に基づいて更に、後述の実施例や栄養組成物の製造法として従来から知られている方法、もしくは今後新しく提供される方法を利用すれば、本発明で目的とする乳清たんぱく栄養組成物を製造することができる。
As mentioned above, although the acidic type liquid enteral nutrient of this invention was demonstrated, this invention is not limited to these, You may add another component, an additive, etc. as needed. For example, additives such as citric acid, tartaric acid, malic acid, succinic acid, lactic acid, glycerin, propylene glycol, gum arabic, pigments, fragrances, preservatives and the like used as usual food ingredients may be added as appropriate. .
In the production of the present invention, based on the composition range described above, if a method conventionally known as a production method of Examples and nutritional compositions described later, or a method newly provided in the future is used, The intended whey protein nutritional composition of the invention can be produced.
本発明における均質化とは、水と油とを含む混合液をエマルションとし、さらにエマルションの液滴を微粒化することである。均質化の一つの方法としては、例えば、回転羽を有する攪拌機、高速回転するディスクやローターと固定ディスクを有するコロイドミル、超音波式乳化機、一種の高圧ポンプである均質機(ホモジナイザー)等が挙げられる。 The homogenization in the present invention is to make a mixed liquid containing water and oil into an emulsion and further atomize the droplets of the emulsion. As one method of homogenization, for example, a stirrer having a rotating blade, a colloid mill having a disk rotating at high speed or a rotor and a fixed disk, an ultrasonic emulsifier, a homogenizer which is a kind of high-pressure pump (homogenizer), etc. Can be mentioned.
本発明における酸性タイプ液状経腸栄養剤は、容器等に充填された状態にあるものも含まれ、その場合、製剤を予め加熱滅菌した後に無菌的に容器に充填する方法(例えばUHT殺菌法とアセプティック充填法を併用する方法)、あるいは容器に充填した後に容器と一緒に加熱滅菌する方法(レトルト殺菌法、ボイル殺菌法)を採用することができる。なお、UHT殺菌法では飲料に直接水蒸気を吹き込むスチームインジェクション式や飲料を水蒸気中に噴射して加熱するスチームインフュージョン式等の直接加熱方式、プレートやチューブ等、表面熱交換機器を用いる間接加熱方式等の公知の方法で行うことができる。いずれの殺菌方式においても130〜150℃、2〜120秒程度の加熱処理が好ましい。レトルト殺菌の場合、110〜125℃、4〜30分程度の加熱処理が好ましい。また、ボイル(高温常圧)殺菌の場合、液状経腸栄養剤のpHが4.6以下で70〜95℃、5〜20分程度の加熱処理が好ましい。 The acidic type liquid enteral nutrient in the present invention includes those in a state of being filled in a container or the like. In this case, a method of filling the container aseptically after preliminarily heat-sterilizing the preparation (for example, UHT sterilization method) A method using the aseptic filling method) or a method of heating and sterilizing the container together with the container (retort sterilization method, boil sterilization method) can be employed. In addition, in the UHT sterilization method, a direct injection method such as a steam injection method in which water vapor is directly blown into the beverage or a steam infusion method in which the beverage is heated by being injected into the water vapor, an indirect heating method using a surface heat exchange device such as a plate or tube It can carry out by well-known methods, such as. In any sterilization method, heat treatment at 130 to 150 ° C. for about 2 to 120 seconds is preferable. In the case of retort sterilization, heat treatment at 110 to 125 ° C. for about 4 to 30 minutes is preferable. In the case of boiled (high temperature and normal pressure) sterilization, the heat treatment is preferably performed at 70 to 95 ° C. for about 5 to 20 minutes when the pH of the liquid enteral nutrient is 4.6 or less.
本発明で得られた酸性タイプ液状経腸栄養剤を収容する容器としては特に限定されないが、患者が摂取しやすい形態であることが好ましい。例えば、プラスチックボトル、ペットボトルやカート缶、テトラパックなどの紙製容器、または、アルミパウチ、もしくは、金属缶などが挙げられる。
使用する容器としては、軟質合成樹脂(例えば可塑化塩化ビニル樹脂、ポリウレタン系樹脂、ポリエチレン(PE)系樹脂、ポリプロピレン(PP)系樹脂、エチレン−酢酸ビニル共重合体(EVA)、エチレン−α−オレフィン共重合体等の各種ポリオレフィン系樹脂、ポリフルオロカーボン、ポリイミド等)により形成された密閉型であり、加熱殺菌可能な軟質容器が好適である。また、紙にアルミ箔、更に容器の内表面側に合成樹脂(例えばポリエチレン)をラミネートした素材により形成された容器等も使用することができ、このラミネート容器は、アセプティック包装法に好適である。
その他にも、医療用容器等に使用されている樹脂を適宜使用することができる。ポリエチレンテレフタレート(PET)、ポリエチレンナフタレート(PEN)、エチレン・ビニルアルコール共重合体(EVOH)、ポリ塩化ビニリデン(PVDC)、ポリアクリロニトリル、ポリビニルアルコール、ポリアミド、ポリエステル等のガスバリア性樹脂層や、アルミ箔、アルミ蒸着フィルム、酸化珪素皮膜、酸化アルミ被膜等のガスバリア性を有する層を、なお、容器に透明性を要求されるときはこれらのうち透明なものを選んで、上記した軟質合成樹脂に必要により適宜組み合わせて、フィルムの層成分として用いることが好ましい。
Although it does not specifically limit as a container which accommodates the acidic type liquid enteral nutrient obtained by this invention, It is preferable that it is a form which a patient can ingest easily. For example, a plastic container, a plastic bottle, a cart can, a paper container such as Tetra Pak, an aluminum pouch, or a metal can.
As a container to be used, soft synthetic resin (for example, plasticized vinyl chloride resin, polyurethane resin, polyethylene (PE) resin, polypropylene (PP) resin, ethylene-vinyl acetate copolymer (EVA), ethylene-α- A flexible container that is a sealed type formed of various polyolefin resins such as an olefin copolymer, polyfluorocarbon, polyimide, and the like and can be heat sterilized is preferable. Moreover, a container formed of a material obtained by laminating a paper and an aluminum foil and a synthetic resin (for example, polyethylene) on the inner surface side of the container can also be used. This laminated container is suitable for the aseptic packaging method.
In addition, resins used in medical containers and the like can be used as appropriate. Gas barrier resin layers such as polyethylene terephthalate (PET), polyethylene naphthalate (PEN), ethylene-vinyl alcohol copolymer (EVOH), polyvinylidene chloride (PVDC), polyacrylonitrile, polyvinyl alcohol, polyamide, polyester, and aluminum foil , Layer with gas barrier properties such as aluminum vapor deposition film, silicon oxide film, aluminum oxide film, etc. If the container is required to be transparent, choose a transparent one of these, and it is necessary for the above soft synthetic resin It is preferable to use as a layer component of a film combining suitably.
本発明の酸性タイプ液状経腸栄養剤の加熱殺菌後の粘度としては、3〜30mPa・s、好ましくは3〜20mPa・s、より好ましくは5〜15mPa・sである。酸性タイプ液状経腸栄養剤の加熱殺菌後の粘度が、30mPa・sより高いと、経管栄養を実施する際、チューブ流動性が悪くなり、酸性タイプ液状経腸栄養剤の投与が困難となる。一方、3mPa・s以上であれば、水の粘度に近く、チューブ流動性に問題なく、チューブの閉塞はない。
粘度の測定は、第7版食品添加物公定書 B.一般試験法 28.粘度測定法 第2法 回転粘度計法で行う。例えば、RB80L形粘度計(東機産業株式会社)を用いて測定した値をいう。
The viscosity of the acidic liquid enteral nutrient of the present invention after heat sterilization is 3 to 30 mPa · s, preferably 3 to 20 mPa · s, more preferably 5 to 15 mPa · s. If the viscosity of the acidic liquid enteral nutrient after heat sterilization is higher than 30 mPa · s, the tube fluidity will deteriorate when tube feeding is carried out, making it difficult to administer the acidic liquid enteral nutrient. . On the other hand, if it is 3 mPa · s or more, it is close to the viscosity of water, there is no problem in tube fluidity, and there is no blockage of the tube.
Viscosity is measured according to the 7th edition Food Additives Official Document. General test method 28. Viscosity measurement method Method 2 Rotational viscometer method For example, it refers to a value measured using an RB80L viscometer (Toki Sangyo Co., Ltd.).
このようにして得られた酸性タイプ液状経腸栄養剤は、たんぱく質、脂質、糖質、ビタミン、ミネラルなどが十分量、バランスよく配合され、乳化安定性が良好で、粘度が低く、チューブ流動性に優れ、チューブに詰まらず、栄養補給を必要とする高齢者や患者などへの栄養補給の際に摂取できるようにすることができる。 The acidic type liquid enteral nutrient obtained in this way contains sufficient amounts of proteins, lipids, sugars, vitamins, minerals, etc. in a well-balanced manner, good emulsification stability, low viscosity, and tube fluidity. It is excellent in that it does not clog the tube and can be taken when feeding nutrition to elderly people or patients who need nutrition.
次に、実施例を挙げて本発明をさらに詳細に説明するが、本発明はこれらに限定されるものではない。
(実施例1)
表1に示す配合に基づき、後述する調製法1の方法により調製し、本発明の酸性タイプ液状経腸栄養剤を得た。得られた酸性タイプ液状経腸栄養剤の粘度は20mPa・sであり、溶出試験第1液と混合しても凝集物が認められず、40℃に30日間保存した後でも、乳化状態は良好であった。
EXAMPLES Next, although an Example is given and this invention is demonstrated further in detail, this invention is not limited to these.
Example 1
Based on the formulation shown in Table 1, it was prepared by the method of Preparation Method 1 described later to obtain the acidic type liquid enteral nutrient of the present invention. The viscosity of the obtained acidic type liquid enteral nutrient is 20 mPa · s, and no agglomerates are observed even when mixed with the first solution of the dissolution test, and the emulsified state is good even after storage at 40 ° C. for 30 days. Met.
(調製法1)
65℃の温水6kgを攪拌しながら、リン酸二水素ナトリウム、クエン酸三カリウム、カゼイン加水分解物としてエマルアップ(平均分子量4600ダルトン、森永乳業株式会社)を少しずつ加え、十分に溶解させた後、デキストリンとしてサンデック#150(三和澱粉工業株式会社)、塩化ナトリウム、塩化カリウム、塩化マグネシウム、グルコン酸カルシウムを加えて十分に攪拌し水相とした。加温した大豆油に乳化剤としてコハク酸モノグリセライドであるコハク酸グリセリンモノステアレート(サンソフトNo.681NU、太陽化学株式会社)を投入し、溶解させて油相とした。水相に油相を混合し、プロペラ攪拌機により5分間の予備乳化を行った後、pH3.8となるようにクエン酸を加え、さらに、ミネラルミックス、ビタミンミックスを加えて十分に攪拌した。その後、水を加えて全量を10kgとし、原料溶液を得た。該原料溶液を高圧均質機により、50MPaの圧力で均質化処理し、これを200mL容チアーパックST(登録商標、株式会社細川洋行)に200mLずつ充填し、密封し、90℃で10分間のボイル殺菌処理を実施し、酸性タイプ液状経腸栄養剤を得た。
(Preparation method 1)
After stirring 6kg of warm water of 65 ° C, add Emul-up (average molecular weight 4600 Dalton, Morinaga Milk Industry Co., Ltd.) little by little as sodium dihydrogen phosphate, tripotassium citrate and casein hydrolyzate As a dextrin, Sandec # 150 (Sanwa Starch Co., Ltd.), sodium chloride, potassium chloride, magnesium chloride and calcium gluconate were added and stirred sufficiently to obtain an aqueous phase. Glycerol monostearate succinate (Sansoft No. 681NU, Taiyo Kagaku Co., Ltd.), which is a monoglyceride succinate, was added to the heated soybean oil as an emulsifier and dissolved to obtain an oil phase. The oil phase was mixed with the water phase, preliminarily emulsified with a propeller stirrer for 5 minutes, citric acid was added so as to have a pH of 3.8, and further, a mineral mix and a vitamin mix were added and sufficiently stirred. Thereafter, water was added to make a total amount of 10 kg to obtain a raw material solution. The raw material solution is homogenized with a high-pressure homogenizer at a pressure of 50 MPa, and 200 mL of Cheerpack ST (registered trademark, Yoko Hosokawa) is filled in 200 mL portions, sealed, and boiled at 90 ° C. for 10 minutes. The sterilization process was implemented and the acidic type liquid enteral nutrient was obtained.
(評価法1)
前述の実施例1、後述する実施例2から5と比較例1から6の液状経腸栄養剤の粘度をRB80L形粘度計(東機産業株式会社)を用いて測定した。結果を表4に示す。
(評価法2)
塩化ナトリウム2.0gを塩酸7.0mLおよび水に溶かして1000mLとした第十五改正日本薬局方溶出試験第1液20mLと実施例1から5と比較例1から6の液状経腸栄養剤10mLを混合した後、100号ふるいを通した際のふるい上に残った凝集物の有無を目視により観察した。結果を表4に示す。
○:凝集物なし。
×:凝集物あり。
(評価法3)
実施例1から5と比較例1から6の液状経腸栄養剤の調製直後および40℃に30日間保存した後の状態を目視により観察した。結果を表4に示す。
○:調製直後および40℃に30日間保存後ともに乳化状態は良好であった。
△:調製直後の乳化状態は良好であったが、40℃に30日間保存した後に油相分離が発生した。
×:調製直後に油相分離が発生した。
(Evaluation method 1)
The viscosities of the liquid enteral nutrients of Example 1 described above and Examples 2 to 5 and Comparative Examples 1 to 6 described later were measured using an RB80L viscometer (Toki Sangyo Co., Ltd.). The results are shown in Table 4.
(Evaluation method 2)
Fifteenth revised Japanese Pharmacopoeia dissolution test 1st solution 20 mL of sodium chloride 2.0 g dissolved in 7.0 mL of hydrochloric acid and water 10 mL of liquid enteral nutrient of Examples 1-5 and Comparative Examples 1-6 After mixing, the presence or absence of aggregates remaining on the sieve when passing through No. 100 sieve was visually observed. The results are shown in Table 4.
○: No aggregate.
X: There exists an aggregate.
(Evaluation method 3)
The state immediately after the preparation of the liquid enteral nutrients of Examples 1 to 5 and Comparative Examples 1 to 6 and after storage at 40 ° C. for 30 days was visually observed. The results are shown in Table 4.
○: The emulsified state was good both immediately after preparation and after storage at 40 ° C. for 30 days.
Δ: The emulsified state immediately after preparation was good, but oil phase separation occurred after storage at 40 ° C. for 30 days.
X: Oil phase separation occurred immediately after preparation.
(比較例1)
実施例1において、カゼイン加水分解物であるエマルアップをカゼインナトリウムであるALANATE180(フォンテラ ジャパン株式会社)に変えた以外は、実施例1と全く同じ調製法を繰り返して経腸栄養剤を得た。得られた経腸栄養剤の粘度は95mPa・sであった。
(比較例2)
実施例1において、カゼイン加水分解物であるエマルアップを乳清たんぱく質であるユニフィックスWT(日本新薬株式会社)に変えた以外は、実施例1と全く同じ調製法を繰り返して経腸栄養剤を得た。得られた経腸栄養剤は殺菌処理後に凝集物を発生した。
(比較例3)
実施例1において、カゼイン加水分解物であるエマルアップを乳清たんぱくペプチドであるLACPRODAN DI−3065(平均分子量1015ダルトン、アーラフーズイングレディエンツジャパン株式会社)に変えた以外は、実施例1と全く同じ調製法を繰り返して経腸栄養剤を得た。得られた経腸栄養剤は調製直後に油相分離が発生した。
(比較例4)
実施例1において、カゼイン加水分解物であるエマルアップを平均分子量470ダルトンのカゼイン加水分解物であるHCP301(タツア・ジャパン株式会社)に変えた以外は、実施例1と全く同じ調製法を繰り返して経腸栄養剤を得た。得られた経腸栄養剤は調製直後に油相分離が発生した。
(比較例5)
実施例1において、カゼイン加水分解物であるエマルアップを平均分子量11670ダルトンのカゼイン加水分解物であるHCP105(タツア・ジャパン株式会社)に変えた以外は、実施例1と全く同じ調製法を繰り返して経腸栄養剤を得た。得られた経腸栄養剤は溶出試験第1液と混合すると、凝集物が認められた。
(Comparative Example 1)
In Example 1, enteral nutrient was obtained by repeating exactly the same preparation method as in Example 1 except that Emal-up, which is a casein hydrolyzate, was changed to ALANATE 180 (Fontera Japan Co., Ltd.), which is sodium caseinate. The viscosity of the obtained enteral nutrient was 95 mPa · s.
(Comparative Example 2)
In Example 1, the same preparation method as in Example 1 was repeated except that emalup, which is a casein hydrolyzate, was changed to UNIFIX WT (Nippon Shinyaku Co., Ltd.), a whey protein. Obtained. The obtained enteral nutrient produced aggregates after sterilization treatment.
(Comparative Example 3)
Except that Example 1 was changed to Emul-up, which was a casein hydrolyzate, with LACPRODAN DI-3065 (average molecular weight 1015 Dalton, Araf's Ingredients Japan Co., Ltd.), a whey protein peptide. The same preparation method was repeated to obtain an enteral nutrient. In the obtained enteral nutrient, oil phase separation occurred immediately after preparation.
(Comparative Example 4)
In Example 1, the same preparation method as in Example 1 was repeated except that Emalup, which is a casein hydrolyzate, was changed to HCP301 (Tatsua Japan Co., Ltd.), which is a casein hydrolyzate having an average molecular weight of 470 Daltons. Enteral nutrient was obtained. In the obtained enteral nutrient, oil phase separation occurred immediately after preparation.
(Comparative Example 5)
In Example 1, the same preparation method as in Example 1 was repeated except that Emalup, which is a casein hydrolyzate, was changed to HCP105 (Tatsua Japan Co., Ltd.), a casein hydrolyzate having an average molecular weight of 11,670 daltons. Enteral nutrient was obtained. When the obtained enteral nutrient was mixed with the first solution of dissolution test, aggregates were observed.
(実施例2)
実施例1において、乳化剤であるコハク酸モノグリセライドをジアセチル酒石酸モノグリセライド(ポエムW−10、理研ビタミン株式会社)に変えた以外は、実施例1と全く同じ調製法を繰り返して酸性タイプ液状経腸栄養剤を得た。得られた酸性タイプ液状経腸栄養剤の粘度は28mPa・sであり、溶出試験第1液と混合しても凝集物が認められず、40℃に30日間保存した後でも、乳化状態は良好であった。
(実施例3)
実施例2において、乳化剤であるジアセチル酒石酸モノグリセライド40gを25gに変えた以外は、実施例2と全く同じ調製法を繰り返して酸性タイプ液状経腸栄養剤を得た。得られた酸性タイプ液状経腸栄養剤の粘度は24mPa・sであり、溶出試験第1液と混合しても凝集物が認められず、40℃に30日間保存した後でも、乳化状態は良好であった。
(Example 2)
In Example 1, the same preparation method as in Example 1 was repeated except that succinic acid monoglyceride as an emulsifier was changed to diacetyltartaric acid monoglyceride (Poem W-10, Riken Vitamin Co., Ltd.). Got. The viscosity of the obtained acidic type liquid enteral nutrient is 28 mPa · s, and no agglomerates are observed even when mixed with the first solution of the dissolution test, and the emulsified state is good even after storage at 40 ° C. for 30 days Met.
(Example 3)
In Example 2, an acidic type liquid enteral nutrient was obtained by repeating exactly the same preparation method as in Example 2 except that 40 g of diacetyltartaric acid monoglyceride as an emulsifier was changed to 25 g. The viscosity of the obtained acidic type liquid enteral nutrient is 24 mPa · s, and no agglomerates are observed even when mixed with the first solution of the dissolution test, and the emulsified state is good even after storage at 40 ° C. for 30 days Met.
(比較例6)
実施例2において、乳化剤であるジアセチル酒石酸モノグリセライド40gを15gに変えた以外は、実施例2と全く同じ調製法を繰り返して経腸栄養剤を得た。得られた経腸栄養剤の粘度は21mPa・sであり、溶出試験第1液と混合しても凝集物が認められなかったが、40℃に30日間保存した後に油相分離が発生した。
(比較例7)
実施例2において、乳化剤であるジアセチル酒石酸モノグリセライドを蒸留モノグリセライド(エマルジーMS、理研ビタミン株式会社)に変えた以外は、実施例2と全く同じ調製法を繰り返して経腸栄養剤を得た。得られた経腸栄養剤の粘度は19mPa・sであり、溶出試験第1液と混合しても凝集物が認められなかったが、40℃に30日間保存した後に油相分離が発生した。
(Comparative Example 6)
In Example 2, the same preparation method as in Example 2 was repeated except that 40 g of diacetyltartaric acid monoglyceride as an emulsifier was changed to 15 g, thereby obtaining an enteral nutrient. The viscosity of the obtained enteral nutrient was 21 mPa · s, and even when mixed with the first solution of the dissolution test, no aggregates were observed. However, oil phase separation occurred after storage at 40 ° C. for 30 days.
(Comparative Example 7)
In Example 2, the same preparation method as in Example 2 was repeated except that diacetyl tartaric acid monoglyceride as an emulsifier was changed to distilled monoglyceride (Emulsy MS, Riken Vitamin Co., Ltd.) to obtain an enteral nutrient. The viscosity of the obtained enteral nutrient was 19 mPa · s, and even when mixed with the first solution of the dissolution test, no aggregates were observed. However, oil phase separation occurred after storage at 40 ° C. for 30 days.
(比較例8)
実施例2において、組成を乳化剤であるジアセチル酒石酸モノグリセライドをポリグリセリン脂肪酸エステル(サンソフトQ−17S、太陽化学株式会社)に変え、以下の調製法2の方法により調製し、液状経腸栄養剤を得た。得られた経腸栄養剤は調製直後に油相分離が発生した。
(調製法2)
65℃の温水6kgを攪拌しながら、リン酸二水素ナトリウム、クエン酸三カリウム、カゼイン加水分解物としてエマルアップを少しずつ加え、十分に溶解させた後、乳化剤、デキストリンとしてサンデック#150、塩化ナトリウム、塩化カリウム、塩化マグネシウム、グルコン酸カルシウムを加えて十分に攪拌し水相とした。加温した大豆油を水相に混合し、プロペラ攪拌機により5分間の予備乳化を行った後、pH3.8となるようにクエン酸を加え、さらに、ミネラルミックス、ビタミンミックスを加えて十分に攪拌した。その後、水を加えて全量を10kgとし、原料溶液を得た。該原料溶液を高圧均質機により、50MPaの圧力で均質化処理し、これを200mL容チアーパックST(株式会社細川洋行)に200mLずつ充填し、密封し、90℃で10分間のボイル殺菌処理を実施し、経腸栄養剤を得た。
(Comparative Example 8)
In Example 2, the diacetyl tartaric acid monoglyceride as an emulsifier was changed to polyglycerin fatty acid ester (Sunsoft Q-17S, Taiyo Kagaku Co., Ltd.) and prepared by the method of Preparation Method 2 below. Obtained. In the obtained enteral nutrient, oil phase separation occurred immediately after preparation.
(Preparation method 2)
While stirring 6 kg of warm water at 65 ° C, add emulup as sodium hydrohydrogen phosphate, tripotassium citrate and casein hydrolysate little by little and dissolve well. Then, Sandek # 150, sodium chloride as emulsifier and dextrin Potassium chloride, magnesium chloride and calcium gluconate were added and stirred well to obtain an aqueous phase. Mix the heated soybean oil into the water phase, preliminarily emulsify for 5 minutes with a propeller stirrer, add citric acid to pH 3.8, add mineral mix and vitamin mix, and stir well did. Thereafter, water was added to make a total amount of 10 kg to obtain a raw material solution. The raw material solution is homogenized at a pressure of 50 MPa with a high-pressure homogenizer, and 200 mL of Cheerpack ST (Yoyuki Hosokawa) is filled 200 ml each, sealed, and boil sterilized at 90 ° C. for 10 minutes. Conducted to obtain enteral nutrient.
本発明は、特定の分子量のカゼイン加水分解物と特定の乳化剤を使用して調製することにより、たんぱく質、脂質、糖質、ビタミン、ミネラルなどが十分量、バランスよく配合され、製造工程中の均質化処理や加熱殺菌処理後も乳化安定性が良好で、粘度が低く、チューブ流動性に優れ、チューブに詰まらず、栄養補給を必要とする高齢者や患者などへの栄養補給の際に摂取できるようにした酸性タイプ液状経腸栄養剤に関するものであって、産業上十分に利用できるものである。 The present invention is prepared by using a casein hydrolyzate having a specific molecular weight and a specific emulsifier, so that a sufficient amount of proteins, lipids, carbohydrates, vitamins, minerals and the like are blended in a well-balanced manner, so that it is homogeneous during the production process. After emulsification treatment and heat sterilization treatment, the emulsion stability is good, the viscosity is low, the tube fluidity is excellent, the tube is not clogged, and it can be ingested when feeding elderly people or patients who need nutrition The present invention relates to an acidic type liquid enteral nutritional solution that can be used industrially.
Claims (2)
たんぱく質が、平均分子量500〜10000ダルトンのカゼイン加水分解物であり;
さらに、乳化剤として、コハク酸モノグリセライド、ジアセチル酒石酸モノグリセライド、クエン酸モノグリセライドおよび乳酸モノグリセライドから選ばれる有機酸モノグリセライドのみを0.2〜1重量%含有し;且つ、
加熱殺菌後の粘度が3〜30mPa・sである;
ことを特徴とする酸性タイプ液状経腸栄養剤。 Protein, lipids, carbohydrates, contain vitamins contact and minerals, pH is an acidic type liquid enteral nutrient in the range of 3-4;
The protein is a casein hydrolyzate having an average molecular weight of 500 to 10,000 daltons ;
Furthermore , as an emulsifier, 0.2 to 1% by weight of only an organic acid monoglyceride selected from succinic acid monoglyceride, diacetyltartaric acid monoglyceride, citric acid monoglyceride and lactic acid monoglyceride ;
The viscosity after heat sterilization is 3 to 30 mPa · s ;
An acidic liquid enteral nutrient characterized by that .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008252242A JP5261114B2 (en) | 2008-09-30 | 2008-09-30 | Acid type liquid enteral nutrient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008252242A JP5261114B2 (en) | 2008-09-30 | 2008-09-30 | Acid type liquid enteral nutrient |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010083774A JP2010083774A (en) | 2010-04-15 |
JP5261114B2 true JP5261114B2 (en) | 2013-08-14 |
Family
ID=42248096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008252242A Active JP5261114B2 (en) | 2008-09-30 | 2008-09-30 | Acid type liquid enteral nutrient |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP5261114B2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5963676B2 (en) * | 2010-09-30 | 2016-08-03 | テルモ株式会社 | Enteral nutrition |
JP5789981B2 (en) * | 2010-12-27 | 2015-10-07 | 日油株式会社 | Liquid nutrition composition |
EP2716164B2 (en) | 2011-05-26 | 2024-06-12 | Kaneka Corporation | Additive and method for producing oil-in-water emulsified food product composition |
BR112014009000A2 (en) * | 2011-10-14 | 2017-05-02 | Abbott Lab | sterile liquid protein supplement |
CN102698101B (en) * | 2012-05-25 | 2014-05-28 | 广东省农业科学院农业生物技术研究所 | Nasal feeding nutritional meal with excellent pipeline fluidity |
JP7116044B2 (en) * | 2017-03-30 | 2022-08-09 | テルモ株式会社 | High calorie nutritional composition and package |
JP7116043B2 (en) * | 2017-03-30 | 2022-08-09 | テルモ株式会社 | High calorie nutritional composition and package |
JP7171248B2 (en) * | 2018-06-08 | 2022-11-15 | テルモ株式会社 | liquid nutritional composition |
WO2023120685A1 (en) * | 2021-12-24 | 2023-06-29 | Morinaga Milk Industry Co., Ltd. | Nutritional composition |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2824598B2 (en) * | 1990-04-06 | 1998-11-11 | 雪印乳業株式会社 | Nutrition composition |
US20050148504A1 (en) * | 2002-11-29 | 2005-07-07 | Nobuhiko Katunuma | Cysteine protease inhibitor |
JP2007126379A (en) * | 2005-11-02 | 2007-05-24 | Yaizu Suisankagaku Industry Co Ltd | Method for producing acidic liquid enteral nutritive preparation |
-
2008
- 2008-09-30 JP JP2008252242A patent/JP5261114B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2010083774A (en) | 2010-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5261114B2 (en) | Acid type liquid enteral nutrient | |
JP5963676B2 (en) | Enteral nutrition | |
JP4344943B2 (en) | Gel composition for protein and calcium supplementation | |
JP4993589B2 (en) | Liquid nutrition composition containing whey peptide | |
JP5779348B2 (en) | Acidic liquid nutritional composition | |
JP2007126379A (en) | Method for producing acidic liquid enteral nutritive preparation | |
JP6277957B2 (en) | Nutritional composition | |
JP5384333B2 (en) | Liquid nutritional composition containing whey protein at high concentration and method for producing the same | |
CN110944659A (en) | High calorie nutritional composition and package | |
JP5421769B2 (en) | Liquid nutrition composition containing sodium in high concentration and method for producing the same | |
WO2015146460A1 (en) | Liquid nutritional composition | |
WO2014016917A1 (en) | Acidic liquid nutrient | |
JP5329280B2 (en) | Acid type liquid enteral nutrient | |
JP6084092B2 (en) | Thorough nutritional composition | |
CN112120221A (en) | High calorie nutritional composition | |
JP6347954B2 (en) | Thorough nutritional composition | |
JP6300600B2 (en) | Nutritional food | |
JP5189817B2 (en) | Whey protein nutritional composition | |
JP2012135257A (en) | Liquid nutritious composition | |
JP6575964B2 (en) | Liquid nutrition composition | |
JP6575962B2 (en) | Thorough nutritional composition | |
JP6753255B2 (en) | Liquid nutritional composition | |
JP7524490B2 (en) | Liquid nutritional composition and packaging | |
WO2015146461A1 (en) | Soybean-protein-containing thick nutritional composition | |
JP6087191B2 (en) | Semisolid nutritional composition for gastrostoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110704 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130124 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130313 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20130313 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130423 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130426 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160502 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5261114 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |